Skip to main content
Clinical Trials/NCT04807868
NCT04807868RecruitingNot Applicable

AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)

AdventHealth Translational Research Institute1 site in 1 country1,250 target enrollmentStarted: April 22, 2021Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
1,250
Locations
1
Primary Endpoint
Creation of a Biobank of Liver Tissue Paired with a Registry of Histological and Clinical Metadata

Study Overview

Brief Summary

The purpose of this study is to create a resource that will advance research that is focused on discovery of novel therapies, risk stratification, and aggressive interventions for those at highest risk for non-alcoholic fatty liver disease (NAFLD). To achieve this, we will generate a biobank of liver tissue collected during standard of care liver biopsies. Paired blood/urine samples, FibroScan and relevant data will also be collected.

Study Design

Study Type
Observational
Observational Model
Other
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Creation of a Biobank of Liver Tissue Paired with a Registry of Histological and Clinical Metadata

Time Frame: Baseline

Secondary Outcomes

  • Creation of a Biobank of Blood and Urine Samples Paired with a Registry of Associated Histological and Clinical Metadata(Baseline with annual follow up for up to 5 years)
  • Change in Liver Fat and Fibrosis Over Time ad Measured with FibroScan Controlled Attenuation Parameter and Vibration Controlled Transient Elastography, respectively(Baseline with annual follow up for up to 5 years)

Investigators

Sponsor
AdventHealth Translational Research Institute
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials